Our Medicines | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom. Adverse Events Reporting

our-medicine1  

Sofosbuvir/Velpatasvir Gilead

Sofosbuvir/Velpatasvir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older.1

Summary of Product Characteristics
Prescribing Information
our medicine_image 2 

Ledipasvir/Sofosbuvir Gilead

Ledipasvir/Sofosbuvir Gilead is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above.2

Please consult the SmPC for hepatitis C virus (HCV) genotype-specific activity.

Summary of Product Characteristics
Prescribing Information
our medicines image 3 

Sofosbuvir/Velpatasvir/Voxilaprevir Gilead

Sofosbuvir/Velpatasvir/Voxilaprevir Gilead is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.3

Summary of Product Characteristics
Prescribing Information
 

Hepcludex®▼ (bulevirtide)

Hepcludex® is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult and paediatric patients 3 years of age and older weighing at least 10 kg with compensated liver disease.4

Summary of Product Characteristics
Prescribing Information
 

LIVDELZI®▼ (seladelpar)

LIVDELZI® has received conditional marketing authorisation for the treatment of primary biliary cholangitis, including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.5

Summary of Product Characteristics
Prescribing Information
Stay up to date

Receive email updates from Gilead, including promotional communications.

Register
References
  1. UK Sofosbuvir/Velpatasvir Gilead Summary of Product Characteristics. https://www.emcpi.com/pi/32177 Accessed October 2025.
  2. UK Ledipasvir/Sofosbuvir Gilead Summary of Product Characteristics. https://www.emcpi.com/pi/38293 Accessed October 2025.
  3. UK Sofosbuvir/Velpatasvir/Voxilaprevir Gilead Summary of Product Characteristics. https://www.emcpi.com/pi/33858 Accessed October 2025.
  4. UK Hepcludex® (bulevirtide) Summary of Product Characteristics. https://www.emcpi.com/pi/41295  Accessed October 2025.
  5. UK LIVDELZI® (seladelpar) Summary of Product Characteristics. https://www.emcpi.com/pi/103133 Accessed October 2025.

UKI-EPC-0077 | October 2025

Adverse events should be reported.

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.